Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 594

1.

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.

2.

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.

Terry S, Yang X, Chen MW, Vacherot F, Buttyan R.

J Cell Biochem. 2006 Oct 1;99(2):402-10. Review.

PMID:
16741972
3.

Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.

Cronauer MV, Schulz WA, Ackermann R, Burchardt M.

Int J Oncol. 2005 Apr;26(4):1033-40.

PMID:
15753999
4.

A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4.

Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP.

J Biol Chem. 2003 Aug 15;278(33):30828-34. Epub 2003 Jun 10.

5.
6.

TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.

Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.

Prostate. 2008 Feb 15;68(3):287-95. doi: 10.1002/pros.20698.

PMID:
18163430
7.

Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.

Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K, Waxman J, Kypta RM.

Cancer Res. 2004 Nov 1;64(21):7918-26. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.

8.

Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells.

Choi HY, Lim JE, Hong JH.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):343-9. doi: 10.1038/pcan.2010.26. Epub 2010 Aug 3.

PMID:
20680030
9.

Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.

Dulinska-Litewka J, McCubrey JA, Laidler P.

Curr Med Chem. 2013;20(1):144-57. Erratum in: Curr Med Chem. 2014;21(32):3717.

PMID:
23033951
10.

Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Wang G, Wang J, Sadar MD.

Cancer Res. 2008 Dec 1;68(23):9918-27. doi: 10.1158/0008-5472.CAN-08-1718.

11.

Beta-catenin signaling in prostate cancer: an early perspective.

Chesire DR, Isaacs WB.

Endocr Relat Cancer. 2003 Dec;10(4):537-60. Review.

12.

Androgen receptor involvement in the progression of prostate cancer.

Suzuki H, Ueda T, Ichikawa T, Ito H.

Endocr Relat Cancer. 2003 Jun;10(2):209-16. Review.

13.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

14.

Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.

Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC.

Cancer Res. 2007 Jun 15;67(12):5747-53.

15.
16.

Redundant expression of canonical Wnt ligands in human breast cancer cell lines.

Benhaj K, Akcali KC, Ozturk M.

Oncol Rep. 2006 Mar;15(3):701-7.

PMID:
16465433
17.

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grygiel JJ, Sutherland RL, Henshall SM.

Prostate. 2007 Jul 1;67(10):1081-90.

PMID:
17476687
18.
19.

Interrogating androgen receptor function in recurrent prostate cancer.

Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, Gambhir SS, Wu L, Carey M.

Cancer Res. 2003 Aug 1;63(15):4552-60.

20.

Androgen activates β-catenin signaling in bladder cancer cells.

Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H.

Endocr Relat Cancer. 2013 May 20;20(3):293-304. doi: 10.1530/ERC-12-0328. Print 2013 Jun.

Supplemental Content

Support Center